Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Johns Hopkins University Center for Tuberculosis Research
Street 1: 1550 Orleans Street
Street 2: 1M.o8
City: Baltimore
Province: Maryland
Post Code: 21231-1002
Country: United States of America
Phone: 14109551755
Organization Email: rchaiss@jhmi.edu
Web Site: http://tbhiv-create.org
Other Online Presence:

Focal Point Contact Information

Salutation: Dr
First Name: Richard
Last Name: Chaisson
Title: Professor of Medicine, Epidemiology and International Health
Email: rchaiss@jhmi.edu
Phone:  

Alternate Focal Point Contact Information

Salutation: Mr.
First Name: Tim
Last Name: Teeter
Title: Project Director
Email: tteeter1@jhmi.edu
Phone:  

General Information

Board Constituency: Technical agencies
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Academic / Research Institution
Organization Type - Secondary: None
Organization Description:
Academic center for laboratory, clinical and epidemiologic study of tuberculosis and TB control.
 
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Advocacy
Delivery of health services and care
Research and Development
Technical Assistance

Other Organization Information

Total number of staff in your organization: 100 +
Number of full-time staff who are directly involved with TB: 100 +
Number of part-time staff who are directly involved with TB: 51 - 99
Number of volunteers who are directly involved with TB: 1 - 5
 
How did you hear about the Stop TB Partnership: Other partners
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Involvement in Stop TB Working Groups
 
Are you a member of a Stop TB national partnership: United States of America
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
The Center for TB Research is actively involved in the Global Plan at the Partnership level through the TB/HIV Committee, the Working Group on New Drugs and the Working Group on New Diagnostics. The Center is the home of the Consortium to Respond Effectively to the AIDS-TB Epidemic (CREATE), funded by the Gates Foundation. In the US, the Center provides leadership in research networks including the TB Trials Consortium, the AIDS Clinical Trials Group and the TB Epidemiology Studies Consortium. We are actively involved in TB control efforts in the US, Brazil, South Africa, India, Malawi, Lesotho and other countries.
 

Geographical Reach

Which country is your headquarters located in: United States of America
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Brazil
China
India
Lesotho
Malawi
Panama
South Africa
Uganda
United States of America
Zambia

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

TB Care Delivery:
Technical assistance for DOTS expansion.

Drug-Resistant TB:
Research on new TB drugs.

TB-HIV:
Global consortium (CREATE) for studies of TB/HIV control and evidence-based advocacy for strengthening policy.

New Diagnostics:
Global research on new diagnostics.

New TB Drugs:
Leadership in clinical trials of new drugs with independent grants and through the TB Trials Consortium and AIDS Clinical Trials Group. Laboratory research on new drugs and regimens in the mouse, guinea pig and rabbit models and basic research on drug development.

Fundamental Research:
Bench research on TB genomics, pathogenesis and biology.

Research:
Global studies of implementation science for TB.

Declaration

Declaration of interests:
No conflicts of interest were delacred.

Application date:  
Last updated: May 9, 2012